A Study of Tocilizumab and Methotrexate in Combination or as Monotherapy in Treatment-Naïve Patients With Early Rheumatoid Arthritis

Roche logo

Roche

Status and phase

Completed
Phase 3

Conditions

Rheumatoid Arthritis

Treatments

Drug: methotrexate
Drug: placebo MTX
Drug: tocilizumab [RoActemra/Actemra]
Drug: placebo TCZ

Study type

Interventional

Funder types

Industry

Identifiers

NCT01034137
ML22497
2009-013316-12

Details and patient eligibility

About

This randomized, double-blind, placebo-controlled study will compare the efficacy with regard to sustained remission and safety of tocilizumab and methotrexate, in combination or as monotherapy, in treatment-naïve patients with early rheumatoid arthritis. Patients will be randomized to receive either tocilizumab (8mg/kg iv every 4 weeks) plus weekly methotrexate (po in ascending doses), or tocilizumab (8mg/kg iv every 4 weeks) plus placebo, or methotrexate plus placebo. Anticipated time on study treatment is 2 years, and target sample size is 300.

Full description

Multi-center, randomized, double-blind, placebo-controlled (double placebo) three-arm parallel group, comparative study. Patients were randomized in a 1:1:1 ratio to one of the following treatments: TCZ 8 milligram (mg)/kilogram (kg) + MTX (Group I: TCZ+MTX) TCZ 8 mg/kg + placeboMTX (Group II: TCZ+placebo) MTX + placeboTCZ (Group III: MTX+placebo) Randomization was stratified by participating center and baseline Disease Activity Score, scoring 28 joints (DAS28) level (<5.1 vs. ≥5.1). Patients were evaluated every 4 weeks and at each visit a decision on dosage changes was made based on efficacy parameters (DAS28) and occurrence of adverse events (AEs). Patients received MTX/placeboMTX in climbing dosages. Hydroxychloroquine (HCQ) was added when remission was not reached with the maximum tolerable dosage (MTD) of MTX/placeboMTX. If after 12 additional weeks remission was not reached, HCQ was stopped and replaced by standard of care therapy (in Group I) or placebo therapy was replaced by the corresponding verum resulting in TCZ+MTX combination therapy (in Groups II and III). In case remission was reached, MTX/placeboMTX and TCZ/placeboTCZ had to be decreased. Patients were followed for a maximum of 24 months

Enrollment

317 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • adult patients, >/=18 years of age
  • early rheumatoid arthritis (disease symptoms <1 year) according to ACR criteria
  • disease activity DAS28 >2.6
  • body weight </=110kg, BMI </=36

Exclusion criteria

  • rheumatic autoimmune disease other than RA
  • current inflammatory joint disease other than RA
  • previous treatment with any DMARD or biologic drug used in the treatment of RA
  • intra-articular, parenteral or oral glucocorticoids used for the arthritis

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

317 participants in 3 patient groups

Tocilizumab + Methotrexate
Experimental group
Description:
Participants will receive intravenous (IV) TCZ 8 mg/kg every four weeks for a maximum of 26 infusions + oral capsules of MTX 10-30 mg/week in climbing dosages of 5 mg starting at 10 mg up till a maximum dosage of 30 mg/week. The weekly dose of MTX will be taken on one particular day of the week.
Treatment:
Drug: tocilizumab [RoActemra/Actemra]
Drug: methotrexate
Tocilizumab + Placebo Methotrexate
Active Comparator group
Description:
Participants will receive IV TCZ 8 mg/kg every four weeks for a maximum of 26 infusions + weekly oral matching placebo MTX capsules in climbing dosages. The weekly dose of placebo MTX will be taken on one particular day of the week.
Treatment:
Drug: tocilizumab [RoActemra/Actemra]
Drug: placebo MTX
Methotrexate + Placebo Tocilizumab
Active Comparator group
Description:
Participants will receive weekly oral MTX in climbing dosages of 5 mg starting at 10 mg up till a maximum dosage of 30 mg/week + matching placebo TCZ IV 8 mg/kg every four week for a maximum of 26 infusions. The weekly dose of MTX will be taken on one particular day of the week.
Treatment:
Drug: placebo TCZ
Drug: methotrexate

Trial contacts and locations

21

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems